Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BHMT | Q93088 | 1/20 | 0.30 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.30 |
| ▸ | EYA2 | O00167 | 1/20 | 0.30 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
| ▸ | ACE | P12821 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14341504 | 0.77 | TDP1 (0.39) | BHMTEYA2APPACETDP1 | |
| SCHEMBL30254769 | 0.74 | — | — | |
| SCHEMBL10207227 | 0.74 | OR51E2 (0.35) | OR51E2TDP1 | |
| SCHEMBL10207203 | 0.74 | OR51E2 (0.35) | OR51E2TDP1 | |
| SCHEMBL27092865 | 0.73 | BHMT (0.38) | BHMTEYA2APPACETDP1 | |
| SCHEMBL27092858 | 0.73 | BHMT (0.38) | BHMTEYA2APPACETDP1 | |
| SCHEMBL6552489 | 0.72 | MAPT (0.36) | OR51E2 | |
| SCHEMBL30854460 | 0.72 | MAPT (0.36) | OR51E2 | |
| SCHEMBL11879039 | 0.72 | GABRR1 (0.43) | BHMT | |
| SCHEMBL652071 | 0.72 | TDP1 (0.36) | OR51E2EYA2APPACETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12070460-B2 | Methods of treating skin cancer with Carboxypeptidase Vitellogenic Like (CPVL) inhibitors | REGENERON PHARMACEUTICALS, INC. (US) | 2024-08-27 | — | — | US | claimed |
| US-20250017929-A1 | Methods Of Treating Skin Cancer With Carboxypeptidase Vitellogenic Like (CPVL) Inhibitors | REGENERON PHARMACEUTICALS, INC. | 2025-01-16 | — | — | US | disclosed |
| US-12070460-B2 | Methods of treating skin cancer with Carboxypeptidase Vitellogenic Like (CPVL) inhibitors | REGENERON PHARMACEUTICALS, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| US-20230037524-A1 | Methods Of Treating Skin Cancer With Carboxypeptidase Vitellogenic Like (CPVL) Inhibitors | REGENERON PHARMACEUTICALS, INC. | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250017929-A1 | Methods Of Treating Skin Cancer With Carboxypeptidase Vitellogenic Like (CPVL) Inhibitors | AGBL2, CPA4, CPB1 | BHMT 1181/4885OR51E2 4509/4885EYA2 1143/4885 |
| US-12070460-B2 | Methods of treating skin cancer with Carboxypeptidase Vitellogenic Like (CPVL) inhibitors | AGBL2, CPA4, CPB1 | BHMT 1181/4885OR51E2 4509/4885EYA2 1143/4885 |
| US-20230037524-A1 | Methods Of Treating Skin Cancer With Carboxypeptidase Vitellogenic Like (CPVL) Inhibitors | AGBL2, CPA4, CPB1 | BHMT 1181/4885OR51E2 4509/4885EYA2 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.